Renatus Tactical I

The trust value per share ($10.18) is above the IPO price, providing a floor for redemptions. However, the company's very low cash on hand ($97,362) outside trust raises risk of running out of funds before a deal is announced, potentially forcing liquidation or a dilutive rescue loan. The convertible note ($250,000) converts at $5.00 per unit, which is a steep discount to trust value, indicating potential dilution for public shareholders if a deal is completed. The deadline is May 2027, but the company's financial condition may accelerate the need for a deal.

This notification does not trigger an automatic extension, alter the stated redemption deadline of May 16, 2027, or adjust the reported trust value of $10.45 per share. The delay reflects administrative and audit coordination rather than a structural change to the SPAC’s mechanics or business combination timeline.

This filing establishes the baseline financials immediately post-IPO. The trust value ($10.08 per share) is confirmed. There are no imminent deadline concerns (deadline is May 2027), no extension votes, no target announced, and no material redemption activity. The post-IPO working capital ($569,066 cash outside trust) is limited but typical for a newly-public SPAC. The July convertible note is unusual: it converts at $5.00 per unit — a significant discount to the trust value — which may signal a need for cash or a potential alignment with a future target.

This filing establishes the baseline trust value ($10.025 per share, but the user notes $10.45 per share, likely after interest), redemption mechanics (24-month deadline, extendable to 30 months), and sponsor commitment. It shows the company is now publicly traded and searching for a target. The working capital deficit pre-IPO indicates the company relied on the IPO proceeds for liquidity. The filing also details warrant terms and lock-up provisions.

This filing officially triggers the SPAC's operational clock and locks the exact per-share redemption math for public investors. The $10.025 trust deposit defines the baseline liquidity available for redemptions or liquidation events, with interest only releaseable to cover franchise and income taxes or permitted withdrawals. Critically, the document outlines a sponsor indemnification pledge intended to shield the trust from third-party claims reducing the balance below $10.025 per share, but management explicitly notes that the sponsor's only identified assets are securities in the company itself, leaving no independent financial reserve to back that guarantee. The filing also flags material execution risks, warning that geopolitical instability, trade tensions, and sanctions related to Russia, Ukraine, and the Middle East could materially and adversely affect the company's ability to identify and close a target within the mandated timeframe.

This is the IPO closing filing for a new SPAC. It establishes the trust value ($10.025/share), the 24-month deadline (May 2027), and the board's unilateral extension capability. The sponsor structure includes Devin Nunes, with its sponsor having a significant financial interest.

These structuring details material shift standard SPAC risk profiles for redeemer and hold shareholders. The $10.025 per-unit trust deposit eliminates the $10.00 baseline convention, while the $0.004 founder share cost combined with anti-dilution conversion rights generates immediate, substantial implied dilution documented in the prospectus. By removing the public shareholder redemption opt-out during board-approved extensions, the filing strips retail investors of their primary leverage mechanism to pressure sponsors toward liquidation or higher trust payouts.

This amendment moves the SPAC closer to completing its IPO and becoming a public vehicle with ~$175M in trust ($10.025 per unit). The updated financials show the sponsor's reduced founder share count and the working capital deficit. The exhibits formalize the lock-up agreements, voting commitments, and related-party arrangements. The filing signals that the IPO may be imminent, giving investors a clearer picture of the sponsor's terms and the risks (dilution, no target selected, conflict of interest disclosures).

Per the company’s own disclosures, the concentrated forfeiture structure and the $0.004 effective founder share price give sponsors 'more of an economic incentive' to target 'riskier, weaker-performing or financially unstable business(es)' than typical sponsors would face. The registration statement indicates non-sponsor investors intend to purchase up to 1,443,182 founder shares from Sponsor HoldCo for $3,500,000 and will receive 721,591 private placement warrants transferred by Sponsor HoldCo at no additional cost.

The filing matters because it locks in the definitive terms of the IPO and provides the full text of the Non-Sponsor Investor Letter Agreement, which governs the conduct of non-sponsor holders of founder shares. The SPAC features a strong management team (including Devin Nunes) with prior SPAC experience (DWAC/TMTG). The trust per-share value is $10.025, and the sponsor's low-cost founder shares ($0.004/share) create significant dilution risk for public shareholders. The SPAC has 24 months (extendable to 30) to complete a deal, with a deadline of May 2027 (or later if extended). The underwriter has a conflict of interest, receiving deferred compensation contingent on a deal.

Gil Savir of Paul Hastings LLP explains that the $6,000 monthly CFO compensation establishes a recurring operational cash drain that reduces the available trust capital heading toward the 2027-05-16 deadline, though the amendment does not invoke extension provisions or alter redemption mechanics. The SEC Staff initially flagged the absence of detailed background on executives Messrs. Nunes and Smith, requesting descriptions of their prior involvement with Yorkville Acquisition Corp.

RTAC is now fully documented for its IPO. The trust is $10.025/share, deadline 24 months (30 months max via board extensions). Redemption mechanics, sponsor economics, dilution tables, and voting agreements are all now in the public record. The sponsor pays $0.004/share for founder shares, plus $1.00/warrant for 3.5M private placement warrants. Non-sponsor institutional investors will purchase up to 1,443,182 founder shares from sponsor for $3.5M. The management team's prior SPAC (DWAC) completed a business combination with TMTG, with very low redemptions (0.1% during extensions, 0.02% at close). The trust is approximately $175.4M ($201.8M if over-allotment fully exercised).

This filing establishes the key terms of the SPAC IPO: trust per share initially $10.025, 24-month deadline (extendable to 30 months), redemption rights for public shareholders, warrants exercisable at $11.50, and sponsor involvement of Eric Swider and Devin Nunes. Investors need to evaluate the trust value, dilution, sponsor conduct, and the management team's track record (including DWAC/TMTG). The document also discloses the sponsor's nominal cost for founder shares, potential conflicts, and the business combination criteria.

Eliminating the $5,000,001 net tangible asset restriction alters the redemption calculus, permitting near-total share redemption without automatically triggering a forced liquidation. The disclosed sponsor cash drains ($15,000 monthly service fees, $300,000 note, potential working capital conversions) directly reduce net proceeds available for acquisition, intensifying dilution exposure for initial investors.

According to the staff’s review, this comment letter dictates the precise terms public shareholders will evaluate against the 2027-05-16 deadline. The explicit focus on the $5,000,001 net tangible asset floor and 15% redemption caps defines the mechanical upper bound on cash returns from the trust account, while detailed inquiries into the $15,000 monthly administrative fee, $300,000 promissory note, and 700,000 preemptive founder share transfers expose insider economic arrangements that directly impact shareholder equity and governance stability.

This filing provides the complete prospectus for the SPAC IPO, including trust per-share value, redemption rights, deadline for business combination, sponsor economics (founder shares at $0.004), and management team backgrounds. Investors can assess the terms and risks before the offering.

What changed: Form 10-K annual report for the fiscal year ended December 31, 2025, filed by Renatus Tactical Acquisition Corp I, a SPAC still searching for a business combination. This is the company's first 10-K since its IPO on May 16, 2025. The IPO raised $241.5 million (24.15 million units at $10.00) and a concurrent private placement of 3.82 million warrants at $1.00 each raised $3.82 million. Net trust deposit was $242.1 million. As of December 31, 2025, trust assets totaled $248.2 million ($10.28 per public share). Cash outside the trust was only $4,031, with working capital of $388,033. The auditor issued a going concern opinion, stating cash is insufficient to operate for the next twelve months. Net income for 2025 was $5.06 million, primarily from interest income. No business combination has been announced. The company has until May 2027 (with possible extensions) to complete a deal. The 10-K documents extensive risk factors, including liquidity risk, sponsor conflicts (management ties to TMTG/Trump), and the ability to find a target. Why it matters: This is the first comprehensive annual report post-IPO, providing critical financial health metrics. The trust value of $10.28 per share is slightly below the $10.45 implied in the user's data, which may affect redemption calculations. The $4,031 cash balance and going concern warning highlight the urgency to complete a business combination or risk liquidation. The filing also confirms the sponsor's commitment to vote in favor of any deal and the absence of a minimum redemption threshold, which could enable a deal even with large redemptions. The focus on cryptocurrency/blockchain and data security sectors provides insight into potential targets. The report is material for investors tracking deadline, trust value, and sponsor conduct.

What changed: A Joint Filing Agreement (Exhibit A) attached to a Schedule 13G beneficial ownership report, executed by Harraden Circle Investments, LLC, its affiliated general partners, limited partnerships, and Frederick V. Fortmiller, Jr. The agreement authorizes a single Schedule 13G filing on behalf of all listed Harraden Circle entities and Mr. Fortmiller for their potential beneficial ownership of Renatus Tactical Acquisition Corp I securities, invoking Rule 13d-1(k). It discloses no share counts, percentage thresholds, acquisition dates, or transaction volumes. Regarding SPAC mechanics, the document contains zero references to redemption deadlines, trust account valuations, extension proposals, target identification progress, or sponsor conduct. The only substantive content is the administrative consolidation of reporting obligations among the named investment vehicles, with all assertions originating exclusively from the signatories themselves. Why it matters: For investors tracking redemption calendars, trust value, extension timelines, deal progress, or sponsor behavior, this filing introduces no operational or mechanical changes. It is a boilerplate compliance attachment that confirms a coordinated reporting bloc but intentionally omits the underlying Schedule 13G data required to assess voting intent, disposition plans, or alignment with management. Without the primary schedule, stakeholders cannot determine whether this group intends to participate in any future redemption wave, vote for an extension, or support a specific acquisition candidate. The filing updates SEC registration procedure but provides no signal on liquidity pressure, sponsor fiduciary conduct, or RTAC's path to deSPAC.

What changed: Quarterly report on Form 10-Q for the period ended September 30, 2025, filed by Renatus Tactical Acquisition Corp I, a blank check company (SPAC) searching for a business combination. The company completed its IPO on May 16, 2025, raising $241.5 million and placing $242.1 million in trust. The trust per-share value has accreted to $10.18 from the initial $10.025 per unit. The company has not yet identified a target. The company issued a $250,000 convertible note to an investor in July 2025. Cash outside trust is only $97,362, leading to substantial doubt about going concern. The company has 24 months from IPO (until May 2027) to complete a business combination, with possible two three-month extensions. Why it matters: The trust value per share ($10.18) is above the IPO price, providing a floor for redemptions. However, the company's very low cash on hand ($97,362) outside trust raises risk of running out of funds before a deal is announced, potentially forcing liquidation or a dilutive rescue loan. The convertible note ($250,000) converts at $5.00 per unit, which is a steep discount to trust value, indicating potential dilution for public shareholders if a deal is completed. The deadline is May 2027, but the company's financial condition may accelerate the need for a deal.

What changed: SEC Form 12b-25, a Notification of Late Filing for the Registrant’s Quarterly Report on Form 10-Q for the period ended September 30, 2025. Renatus Tactical Acquisition Corp I formally notified the SEC that it will miss the original filing deadline for its Q3 2025 10-Q. The registrant indicated that the Company and its external auditor require additional time to complete the final review of the financial statements and related disclosures. The filing commits to submitting the delayed report no later than the fifth calendar day following the prescribed due date. Why it matters: This notification does not trigger an automatic extension, alter the stated redemption deadline of May 16, 2027, or adjust the reported trust value of $10.45 per share. The delay reflects administrative and audit coordination rather than a structural change to the SPAC’s mechanics or business combination timeline.

What changed: Schedule 13G/A Joint Filing Agreement (Exhibit A) and associated beneficial ownership amendment cover identifiers. This document is a Joint Filing Agreement executed on August 14, 2025, by Harraden Circle Investments, LLC; Harraden Circle Investors GP, LP; Harraden Circle Investors GP, LLC; Harraden Circle Investors, LP; Harraden Circle Special Opportunities, LP; Harraden Circle Strategic Investments, LP; and Frederick V. Fortmiller, Jr. Acting under Rule 13d-1(k), the seven affiliated entities and Mr. Fortmiller consolidate their SEC reporting into a single Schedule 13G/A submission. The provided text contains only the signature blocks and corporate chain-of-command declarations; it does not include the actual 13G/A schedule pages that would disclose aggregate share counts, percentage of outstanding common stock, date of last purchase, or stated acquisition purpose. Consequently, the filing does not modify RTAC’s $10.45 trust-per-share baseline, its May 16, 2027 redemption deadline, or its SEARCHING status. No amendments to sponsor arrangements, liquidation clocks, or de-SPAC timelines are referenced. Why it matters: Because the submission references a Schedule 13G (not a 13D), the undersigned Harraden Circle parties and Mr. Fortmiller represent themselves as passive investors lacking voting direction or investment decision-making authority, signaling no activist intent, sponsor replacement pressure, or demand to accelerate or defer a business combination. For investors tracking redemption mechanics, sponsor conduct, and deal progress, this confirms the group maintains a passive holding posture without altering the SPAC’s operational parameters. The excerpt contains zero claims attributable to any issuer chief executive, board member, or financial advisor regarding customer concentration, revenue runs, addressable market size, proprietary technology, strategic partnerships, ongoing litigation, or leadership transitions. Exact ownership percentages and total acquired shares remain unverifiable until the corresponding 13G/A schedule data is filed separately.

What changed: A Joint Filing Agreement submitted as Exhibit 99.1 to a Schedule 13G, executed on August 14, 2025, by International SPAC Management Group I LLC, Global Client Advisory Group, and Eric Swider. The instrument formally authorizes these three Reporting Persons to collectively file a beneficial ownership statement regarding Class A ordinary shares (par value of $0.0001 per share) of Renatus Tactical Acquisition Corp I, a Cayman Islands company, and grants mutual permission to submit all future amendments on each other's behalf. The filing updates the regulatory reporting arrangement among the listed holders but discloses zero movements in share counts, acquisition dates, purchase prices, voting power, or investment discretion. It does not modify the tracked $10.45 per share trust value, the May 16, 2027 business combination deadline, or the SEARCHING status. No extension proposals, redemption triggers, target negotiations, or sponsor conduct adjustments are referenced or implied. Why it matters: The document contains no operational or strategic claims regarding customers, revenue, market size, technology, partnerships, litigation, or personnel. All descriptive elements (e.g., Cayman Islands incorporation, $0.0001 par value) are administrative declarations by the filers, not assertions by RTAC management or the sponsor. For investors monitoring deal progression or shareholder economics, this filing is procedurally neutral; substantive developments will only become visible through subsequent individual or aggregated Schedule 13G/13D amendments revealing net position changes, or through definitive proxy/merger documentation detailing target selection, extension voting, or trust liquidation mechanics.

What changed: Quarterly report (Form 10-Q) for the period ended June 30, 2025. This is the first quarterly report since RTAC completed its IPO on May 16, 2025. The filing establishes the baseline balance sheet, trust value, and capital structure of the post-IPO SPAC. It reports trust assets of $243,344,556, which corresponds to a per-share value of approximately $10.08 per public share against an initial trust deposit of $10.025 per unit. The company recognized formation and operating expenses of $445,972 and interest income of $1,240,806, yielding net income of $794,834 for the partial period. A subsequent event on July 24, 2025, discloses a $250,000 convertible promissory note issued to an investor, convertible into units at $5.00. Sponsor conduct: The Sponsor surrendered for cancellation 3,740,591 Founder Shares on March 13, 2025 and received 1,168,548 new shares on May 14, 2025, resulting in 7,011,288 Class B shares outstanding. Institutional investors and directors purchased 1,545,376 Founder Shares from the Sponsor for $3,800,032. The Sponsor also received 772,688 Private Placement Warrants transferred to non-Sponsor investors at no cost as an inducement. Why it matters: This filing establishes the baseline financials immediately post-IPO. The trust value ($10.08 per share) is confirmed. There are no imminent deadline concerns (deadline is May 2027), no extension votes, no target announced, and no material redemption activity. The post-IPO working capital ($569,066 cash outside trust) is limited but typical for a newly-public SPAC. The July convertible note is unusual: it converts at $5.00 per unit — a significant discount to the trust value — which may signal a need for cash or a potential alignment with a future target.

What changed: This document IS a routine compliance exhibit—a Joint Filing Statement pursuant to Rule 13d-1(k)(1) attached to a Schedule 13G/A for Renatus Tactical Acquisition Corp I. The filing text records only administrative consents from Boothbay Fund Management LLC, Boothbay Absolute Return Strategies, LP, and Ari Glass to jointly file their Schedule 13G. It reports zero changes to redemption mechanics, trust value, the business combination deadline, deal progress, or sponsor conduct. No share quantities, ownership percentages, or acquisition activity are disclosed in this exhibit. Why it matters: As a procedural consent, it carries no direct weight on capital deployment timelines or unit redemptions. It does, however, confirm that Boothbay’s entities continue maintaining a reportable equity position in the SEARCHING SPAC. Future Schedule 13G/A amendments will dictate whether this stake influences pro forma ownership calculations ahead of a merger or remains passive. Until numerical disclosures appear in subsequent filings, investors cannot assess potential impact on target selection, extension votes, or liquidation mechanics. All observations regarding future influence derive from standard SEC reporting sequences, not from this consent exhibit.

What changed: Quarterly report (Form 10-Q) for Renatus Tactical Acquisition Corp I for the period ended March 31, 2025, filed June 25, 2025. The report covers the company's pre-IPO period and includes subsequent events for the IPO consummated on May 16, 2025. This is the first quarterly report after the IPO. The financial statements as of March 31, 2025, reflect only deferred offering costs ($1.22M), accrued offering costs ($1.11M), and a related party payable ($111K), with no cash and a working capital deficit of $1.20M. The IPO closed after the quarter on May 16, 2025, raising $241.5M in gross proceeds plus $3.82M from private placement warrants, with $10.025 per unit placed in trust. Sponsor shares were surrendered and reissued; the sponsor now owns 7,011,288 Class B shares. No business combination has been announced. Why it matters: This filing establishes the baseline trust value ($10.025 per share, but the user notes $10.45 per share, likely after interest), redemption mechanics (24-month deadline, extendable to 30 months), and sponsor commitment. It shows the company is now publicly traded and searching for a target. The working capital deficit pre-IPO indicates the company relied on the IPO proceeds for liquidity. The filing also details warrant terms and lock-up provisions.

What changed: Form 3 initial statement of beneficial ownership of securities, classified as a routine compliance exhibit. The filing states that Director Lambert Randall Thomas Jr. reported no non-derivative transactions or holdings. No adjustments to the trust account ($10.45 per share), the redemption deadline (2027-05-16), extension provisions, or business combination progress are disclosed within this submission. Why it matters: This filing functions as a compliance exhibit establishing the baseline for insider position reporting before subsequent Forms 4. Because it records zero non-derivative equity movements or holdings for the named director, it provides no data on sponsor funding, side agreements, or pre-deal share accumulation that typically influences redemption calculus or deal execution. Investors tracking the $10.45 trust amount and 2027-05-16 timeline should monitor future filings for any deviation from this zero-disclosure posture, as subsequent entries would signal shifts in director alignment, capital commitment, or exit positioning ahead of the redemption window.